抗ＣＸＣＲ３抗体 - GENZYME CORPORATION

Title:

抗ＣＸＣＲ３抗体

Document Type and Number:

Japanese Patent JP6646100

Kind Code:

B2

Abstract:

The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.

More Like This:

WO/2023/036137	PROCESS FOR PREPARING HIGHLY HOMOGENOUS ANTIBODY-DRUG CONJUGATES FOR ENGINEERED ANTIBODIES
WO/2000/067795	IMMUNOTHERAPY OF B-CELL MALIGNANCIES USING ANTI-CD22 ANTIBODIES
WO/2016/124781	NANOBODY DIMERS LINKED VIA C-TERMINALLY ENGINEERED CYSTEINS

Inventors:

Michelle Eude
Jennifer tedstone
Tracy Roddy
Karen Bee Carter
Timothy Dee Connors
Jason Robert Pinkney
Elizabeth Masterjohn
Louis In Chu

Application Number:

JP2018089004A

Publication Date:

February 14, 2020

Filing Date:

May 07, 2018

Export Citation:

Click for automatic bibliography generation Help

Assignee:

GENZYME CORPORATION

International Classes:

C07K16/28; A61K39/395; A61P3/10; C12N15/13; C12P21/08; G01N33/53

Domestic Patent References:

JP2002513388A
JP2010517531A

Attorney, Agent or Firm:

Junji Yuda
Noriyuki Takebayashi

Previous Patent: ユーザ装置、基地局、情報通知方法及び情報受信方法

Next Patent: 荷役機械用制動装置